JP2022551813A5 - - Google Patents

Info

Publication number
JP2022551813A5
JP2022551813A5 JP2022515099A JP2022515099A JP2022551813A5 JP 2022551813 A5 JP2022551813 A5 JP 2022551813A5 JP 2022515099 A JP2022515099 A JP 2022515099A JP 2022515099 A JP2022515099 A JP 2022515099A JP 2022551813 A5 JP2022551813 A5 JP 2022551813A5
Authority
JP
Japan
Application number
JP2022515099A
Other languages
Japanese (ja)
Other versions
JP2022551813A (ja
JPWO2021046398A5 (https=
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2020/049473 external-priority patent/WO2021046398A2/en
Publication of JP2022551813A publication Critical patent/JP2022551813A/ja
Publication of JP2022551813A5 publication Critical patent/JP2022551813A5/ja
Publication of JPWO2021046398A5 publication Critical patent/JPWO2021046398A5/ja
Pending legal-status Critical Current

Links

JP2022515099A 2019-09-04 2020-09-04 麻疹に対する併用抗ウイルス療法 Pending JP2022551813A (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201962895752P 2019-09-04 2019-09-04
US62/895,752 2019-09-04
US202062988286P 2020-03-11 2020-03-11
US62/988,286 2020-03-11
US202063009883P 2020-04-14 2020-04-14
US63/009,883 2020-04-14
PCT/US2020/049473 WO2021046398A2 (en) 2019-09-04 2020-09-04 Combination antiviral therapy for measles

Publications (3)

Publication Number Publication Date
JP2022551813A JP2022551813A (ja) 2022-12-14
JP2022551813A5 true JP2022551813A5 (https=) 2023-09-13
JPWO2021046398A5 JPWO2021046398A5 (https=) 2023-09-13

Family

ID=74853434

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022515099A Pending JP2022551813A (ja) 2019-09-04 2020-09-04 麻疹に対する併用抗ウイルス療法

Country Status (6)

Country Link
US (1) US20230014151A1 (https=)
EP (1) EP4025586A4 (https=)
JP (1) JP2022551813A (https=)
CN (1) CN114729007A (https=)
IL (1) IL291091A (https=)
WO (1) WO2021046398A2 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022159372A1 (en) * 2021-01-22 2022-07-28 Decoy Therapeutics, Inc. Methods and compositions for treating infections
WO2023150375A2 (en) * 2022-02-07 2023-08-10 Decoy Therapeutics Inc. Methods and compositions for treating covid infections
WO2025085916A1 (en) * 2023-10-20 2025-04-24 The Trustees Of Columbia University In The City Of New York Humanized monoclonal antibody and vaccines against measles virus
WO2025111546A1 (en) * 2023-11-22 2025-05-30 Board Of Trustees Of Michigan State University Development of broad-spectrum anti-opioid vaccines

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK1692265T3 (da) * 2003-11-04 2011-11-21 Univ Tulane Fremgangsmåde til hindring af en virus-celle-fusion ved hæmning af fusionsinitieringsområdets funktion i RNA-vira med klasse 1-membranfusogene envelopeproteiner
CN101687911A (zh) * 2007-05-16 2010-03-31 康久化学生物技术公司 抗病毒肽的半胱磺酸衍生物
WO2012020108A2 (en) * 2010-08-11 2012-02-16 Cormus Srl Multimeric inhibitors of viral fusion and uses thereof
US10172961B2 (en) * 2014-05-07 2019-01-08 Cornell University Inhibitors of fusion between viral and cell membranes as well as compositions and methods of using them

Similar Documents

Publication Publication Date Title
BR112023005462A2 (https=)
BR112023012656A2 (https=)
BR112021014123A2 (https=)
BR112023009656A2 (https=)
BR112022009896A2 (https=)
JP2022551813A5 (https=)
BR112021017747A2 (https=)
BR112022024743A2 (https=)
BR112022026905A2 (https=)
BR112023011738A2 (https=)
BR112023004146A2 (https=)
BR112023006729A2 (https=)
BR102021018859A2 (https=)
BR112023016292A2 (https=)
BR112023011539A2 (https=)
BR112023011610A2 (https=)
BR112023008976A2 (https=)
BR102021020147A2 (https=)
BR102021018926A2 (https=)
BR102021018167A2 (https=)
BR102021017576A2 (https=)
BR102021016837A2 (https=)
BR102021016551A2 (https=)
BR102021016375A2 (https=)
BR102021016176A2 (https=)